Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (210)	6/4/1998 3:06:00 PM
From: Anthony Wong	Respond to of 1722

Pharmacia & Upjohn Still Studying Impotence Treatments June 04, 1998 1:10 PM LONDON (Dow Jones)--Pharmacia & Upjohn Inc. (PNU) said Thursday that it's conducting "follow-up" research on its Caverject anti-impotence drug. But the Swedish-U.S. drugs company sought to play down market talk that it's working on a rival product to Viagra, Pfizer Inc.'s (PFE) oral impotence drug that has already captured 90% of the U.S. market for treating the ailment. A spokesman for Pharmacia & Upjohn said the company doesn't comment on early stage drug trials. But he added "we have said nothing to make people think we're working on some secret new compound." Pharmacia & Upjohn noted, however, that it's conducting routine follow-up studies on injectable impotence drug Caverject. Sales of Caverject rose 10% to $27 million during the fourth quarter and were up 26% on the year to $88 million. Earlier Thursday, Pharmacia & Upjohn's head of research and development, Goran Ando, was quoted as saying the company is working on "several new treatments for impotence." Since Viagra hit the shelves, the industry's focus has been squared on oral impotence treatments. While injectable drugs like Caverject have been around for some time, until Viagra's launch, the true size of the market wasn't apparent. -By Erik Portanger; 44.171.832.8166; eportanger@ap.org